Full Text View
Tabular View
No Study Results Posted
Related Studies
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD (DB2113361)
This study has been completed.
Study NCT01313637   Information provided by GlaxoSmithKline

First Received on March 10, 2011.   Last Updated on April 11, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Chronic Disease
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiration Disorders
More general conditions related to this trial
Disease Attributes
Pathologic Processes
Respiratory Tract Diseases
Interventions listed in this trial
125/25mcg
125mcg
25mcg
Placebo
Sponsors listed in this trial
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services